These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23340239)

  • 1. Dualities of living with HIV/HCV co-infection: patients' perspectives from those who are ineligible for or nonresponsive to treatment.
    Farrell G; Comiskey C
    J Assoc Nurses AIDS Care; 2014; 25(1):9-22. PubMed ID: 23340239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of factors associated with the quality of life of patients living with HIV/HCV co-infection.
    Pereira M; Fialho R
    J Behav Med; 2016 Oct; 39(5):767-81. PubMed ID: 27506910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coinfection with hepatitis C virus and HIV].
    Ruys TA; Reesink HW; Lange JM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2056-60. PubMed ID: 14606352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.
    Andreoni M; Giacometti A; Maida I; Meraviglia P; Ripamonti D; Sarmati L
    Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1473-83. PubMed ID: 23111959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
    Braitstein P; Montessori V; Chan K; Montaner JS; Schechter MT; O'Shaughnessy MV; Hogg RS
    AIDS Care; 2005 May; 17(4):505-15. PubMed ID: 16036236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients.
    Buti M; Wong J; Casado MA; Esteban R
    J Hepatol; 2006; 44(1 Suppl):S60-4. PubMed ID: 16360235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
    Marcellin F; Demoulin B; Spire B; Suzan-Monti M; Roux P; Protopopescu C; Sagaon-Teyssier L; Duracinsky M; Dray-Spira R; Carrieri MP;
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):701-13. PubMed ID: 25723557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia.
    Erqou S; Mohanty A; McGinnis KA; Vanasse G; Freiberg MS; Sherman KE; Butt AA
    J Viral Hepat; 2013 Jul; 20(7):463-9. PubMed ID: 23730839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seeking serenity: living with HIV/AIDS in rural Western Canada.
    Groft JN; Robinson Vollman A
    Rural Remote Health; 2007; 7(2):677. PubMed ID: 17516839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenge of hepatitis C in the HIV-infected person.
    Thomas DL
    Annu Rev Med; 2008; 59():473-85. PubMed ID: 18186707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection.
    Fleming CA; Christiansen D; Nunes D; Heeren T; Thornton D; Horsburgh CR; Koziel MJ; Graham C; Craven DE
    Clin Infect Dis; 2004 Feb; 38(4):572-8. PubMed ID: 14765352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis.
    Künzler-Heule P; Fierz K; Schmidt AJ; Rasi M; Bogdanovic J; Kocher A; Engberg S; Battegay M; Nöstlinger C; Lehner A; Kouyos R; Schmid P; Braun DL; Fehr J; Nicca D
    BMC Infect Dis; 2021 Apr; 21(1):319. PubMed ID: 33823783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of end-stage liver disease in HIV/hepatitis C virus co-infection.
    Spengler U
    Curr Opin HIV AIDS; 2011 Nov; 6(6):527-33. PubMed ID: 21918437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.
    Fleming CA; Craven DE; Thornton D; Tumilty S; Nunes D
    Clin Infect Dis; 2003 Jan; 36(1):97-100. PubMed ID: 12491208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China.
    Chen X; He JM; Ding LS; Zhang GQ; Zou XB; Zheng J
    Arch Virol; 2013 Sep; 158(9):1889-94. PubMed ID: 23553454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV and hepatitis C virus coinfection: bad bedfellows.
    Schooley RT
    Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.